Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 362

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

Open access
The I-SPY 1 TRIAL Investigators, Esserman, Laura J., Berry, Donald A., Cheang, Maggie C. U., Yau, Christina, Perou, Charles M., Carey, Lisa, DeMichele, Angela, Gray, Joe W., Conway-Dorsey, Kathleen, Lenburg, Marc E., Buxton, Meredith B., Davis, Sarah E., van’t Veer, Laura J., Hudis, Clifford, Chin, Koei, Wolf, Denise, Krontiras, Helen, Montgomery, Leslie, Tripathy, Debu, Lehman, Constance, Liu, Minetta C., Olopade, Olufunmilayo I., Rugo, Hope S., Carpenter, John T., Livasy, Chad, Dressler, Lynn, Chhieng, David, Singh, Baljit, Mies, Carolyn, Rabban, Joseph, Chen, Yunni-Yi, Giri, Dilip, Au, Alfred, Hylton, Nola·2012·Breast Cancer Research and Treatment

Abstract

Neoadjuvant chemotherapy for breast cancer allows individual tumor response to be assessed depending on molecular subtype, and to judge the impact of response to therapy on recurrence-free survival (RFS). The multicenter I-SPY 1 TRIAL evaluated patients with ≥ 3 cm tumors by using early imaging and molecular signatures, with outcomes of pathologic complete response (pCR) and RFS. The current analysis was performed using data from patients who had molecular profiles and did not receive trastuzumab. The various molecular classifiers tested were highly correlated. Categorization of breast cancer by molecular signatures enhanced the ability of pCR to predict improvement in RFS compared to the population as a whole. In multivariate analysis, the molecular signatures that added to the ability of HR and HER2 receptors, clinical stage, and pCR in predicting RFS included 70-gene signature, wound healing signature, p53 mutation signature, and PAM50 risk of recurrence. The low risk signatures were associated with significantly better prognosis, and also identified additional patients with a good prognosis within the no pCR group, primarily in the hormone receptor positive, HER-2 negative subgroup. The I-SPY 1 population is enriched for tumors with a poor prognosis but is still heterogeneous in terms of rates of pCR and RFS. The ability of pCR to predict RFS is better by subset than it is for the whole group. Molecular markers improve prediction of RFS by identifying additional patients with excellent prognosis within the no pCR group.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10549-011-1895-2

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Cited by

See all 362

Metadata

Authors
The I-SPY 1 TRIAL Investigators, Esserman, L. J., Berry, D. A., Cheang, M. C. U., Yau, C., Perou, C. M., Carey, L., DeMichele, A., Gray, J. W., Conway-Dorsey, K., Lenburg, M. E., Buxton, M. B., Davis, S. E., van’t Veer, L. J., Hudis, C., Chin, K., Wolf, D., Krontiras, H., Montgomery, L., Tripathy, D., Lehman, C., Liu, M. C., Olopade, O. I., Rugo, H. S., Carpenter, J. T., Livasy, C., Dressler, L., Chhieng, D., Singh, B., Mies, C., Rabban, J., Chen, Y.-Y., Giri, D., Au, A., & Hylton, N.
Venue
Breast Cancer Research and Treatment
Published
2011-12-25
Volume
132
Issue
3
Pages
1049-1062
ISSN
  • 0167-6806 (ISSN-L)
  • 1573-7217
OpenAlex
W2147908679
Cited by
362
References
45
FWCI
8.54
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). https://app.cochat.ai/papers/10.1007/s10549-011-1895-2
The paper
The I-SPY 1 TRIAL Investigators, Esserman, L. J., Berry, D. A., Cheang, M. C. U., Yau, C., Perou, C. M., Carey, L., DeMichele, A., Gray, J. W., Conway-Dorsey, K., Lenburg, M. E., Buxton, M. B., Davis, S. E., van’t Veer, L. J., Hudis, C., Chin, K., Wolf, D., Krontiras, H., Montgomery, L., . . . Hylton, N. (2012). Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-011-1895-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.